Results 11 to 20 of about 2,820 (114)

Incidence of Infusion Reactions and Clinical Effectiveness of Intravenous Golimumab Versus Infliximab in Patients with Rheumatoid Arthritis: The Real-World AWARE Study [PDF]

Rheumatology and Therapy, 2021
Evaluate tolerability and effectiveness of golimumab-IV versus infliximab in patients with rheumatoid arthritis (RA) in a real-world setting.AWARE, a prospective, real-world, pragmatic, observational, multicenter, phase 4 study, enrolled RA patients when initiating golimumab-IV or infliximab. Treatment decisions were made by the treating rheumatologist.
, Soumya D Chakravarty, Shelly Kafka
exaly   +4 more sources

Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis [PDF]

Arthritis and Rheumatology, 2017
Objective To evaluate the safety and efficacy of intravenous ( IV ) golimumab treatment in psoriatic arthritis (PsA). Methods
Arthur Kavanaugh, M Elaine Husni, Diane D Harrison   +2 more
exaly   +4 more sources

Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients With Early and Late Disease Through One Year of the GO-ALIVE Study [PDF]

JCR: Journal of Clinical Rheumatology, 2022
Background/Objective This post hoc analysis assessed efficacy and safety of intravenous (IV) golimumab in ankylosing spondylitis (AS) patients with early disease (ED) versus late disease (LD). Methods The phase 3, double-blind, GO-ALIVE study randomized patients to IV golimumab 2 mg/
Deodhar, Atul A., Shiff, Natalie J., Gong, Cinty, Hsia, Elizabeth C., Lo, Kim Hung, Kim, Lilliane, Xu, Stephen, Reveille, John D.   +7 more
europepmc   +8 more sources

Efficacy and Safety of Intravenous Golimumab Through One Year in Patients With Active Psoriatic Arthritis [PDF]

Arthritis Care & Research, 2020
ObjectiveThe present study was undertaken to evaluate the safety and efficacy of intravenous (IV) golimumab in patients with active psoriatic arthritis (PsA) through 1 year.MethodsGO‐VIBRANT was a phase III, randomized, placebo‐controlled trial of 480 adults with active PsA. Patients were randomized to receive IV placebo (n = 239) or golimumab 2 mg/kg (
Husni, M. Elaine, Kavanaugh, Arthur, Murphy, Frederick, Rekalov, Dmytro, Harrison, Diane D., Kim, Lilianne, Lo, Kim Hung, Leu, Jocelyn H., Hsia, Elizabeth C.   +8 more
openaire   +3 more sources

The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients [PDF]

Drugs in R&D, 2018
For patients with rheumatoid arthritis (RA) who do not respond or lose response to anti-tumor necrosis factor (TNF) biologics, switching to a different anti-TNF can be an effective means to manage symptoms and disease progression. This study examined the utilization and effectiveness of intravenous golimumab within a real-world population of patients ...
Bray, Vance J., Broadwell, Aaron, Baraf, Herbert S. B., Black, Shawn, Brady, Brenna L., Tkacz, Joseph, Yarngo, Lorraine, DeHoratius, Raphael J.   +7 more
openaire   +3 more sources

Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial [PDF]

Arthritis Research & Therapy, 2020
Background In the GO-VIBRANT trial of intravenous golimumab in psoriatic arthritis (PsA), golimumab significantly inhibited radiographic progression.
Philip Mease, M. Elaine Husni, Shelly Kafka, Soumya D. Chakravarty, Diane D. Harrison, Kim Hung Lo, Stephen Xu, Elizabeth C. Hsia, Arthur Kavanaugh   +8 more
doaj   +2 more sources

Model-Based Design of Sustained-Release Formulations of Anti-TNF-α Monoclonal Antibodies for Intravitreal Administration [PDF]

Pharmaceutics
Background/Objectives: While intravitreal administration allows for increased ocular exposure to anti-TNF-α monoclonal antibodies, there is still a need for developing delivery systems able to prolong ocular drug exposure and alleviate patient compliance
Javier Reig-López, Marina Cuquerella-Gilabert, Javier Zarzoso-Foj, Víctor Mangas-Sanjuán, Virginia Merino, Matilde Merino-Sanjuán   +5 more
doaj   +2 more sources

Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trial [PDF]

Rheumatology, 2013
To evaluate the effects of the anti-TNF-α monoclonal antibody golimumab, administered by s.c. injection or i.v. infusion, on markers of inflammation in patients with RA.In this phase 1, open-label study, patients with active RA were randomized to receive s.c.
Mittie K Doyle, Mahboob U Rahman, Charles A Birbara   +2 more
exaly   +3 more sources

Golimumab-associated myocarditis with progressive eosinophilia after route switch in rheumatoid arthritis [PDF]

European Journal of Case Reports in Internal Medicine
Introduction: Tumour necrosis factor-alpha (TNF-alpha) inhibitors are cornerstone therapies in rheumatoid arthritis (RA) and generally reduce cardiovascular events.
Stephanie Ammari, Nawras Ibrahim
doaj   +2 more sources

A real-world, multi-site, observational study of infusion time and treatment satisfaction with rheumatoid arthritis patients treated with intravenous golimumab or infliximab [PDF]

Journal of Medical Economics, 2018
Objectives: To assess real-world infusion times for golimumab (GLM-IV) and infliximab (IFX) for rheumatoid arthritis (RA) patients and factors associated with treatment satisfaction. Methods: An observational study assessed infusion time including: clinic visit duration, RA medication preparation and infusion time, and infusion process time ...
Shoshana R, Daniel, John D, McDermott, Cathy, Le, Christine A, Pierce, Michael A, Ziskind, Lorie A, Ellis   +5 more
exaly   +3 more sources